Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer
OBJECTIVES:
- Determine the qualitative and quantitative expression of OX-40 and related markers in
sentinel lymph nodes previously removed from patients with cancer.
- Determine the qualitative and quantitative expression of OX-40 and related markers in
sentinel lymph nodes freshly removed from patients with cancer.
- Correlate the expression of OX-40 and related markers in sentinel lymph node tissue
with expression in nonsentinel tissue from primary tumors and nonsentinel lymph nodes,
tumor stage, and patient outcomes.
OUTLINE: Sections of primary tumors, nonsentinel lymph nodes, and sentinel lymph nodes will
be analyzed for expression of OX-40 by immunohistochemistry. Sections of negative (no tumor
metastases) lymph nodes will be used as internal controls. Fresh tissue and blood will be
tested for marker analysis and in vitro assays of immune function.
PROJECTED ACCRUAL: A total of 100 specimens from sentinel lymph nodes previously removed
from cancer patients and 100 specimens from sentinel lymph nodes freshly removed from cancer
patients will be accrued for this study.
Observational
Observational Model: Cohort, Time Perspective: Retrospective
OX-40 expression
The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining
During immunostaining
No
John T. Vetto, MD, FACS
Principal Investigator
OHSU Knight Cancer Institute
United States: Institutional Review Board
CDR0000443230
NCT00900302
April 2005
March 2011
Name | Location |
---|---|
OHSU Knight Cancer Institute | Portland, Oregon 97239 |